MeiraGTx completes initial closing of strategic collaboration with Hologen Limited

• MeiraGTx completed initial closing of strategic collaboration with Hologen on April 20, 2026.
• Collaboration covers research, development, manufacturing, and commercialization of MeiraGTx gene therapies for Parkinson’s disease and genetic obesity disorders.
• Partnership also includes development of proprietary delivery device for local administration of gene therapy to central nervous system.
• Hologen previously paid USD 105 million toward USD 200 million upfront payment under March 2025 framework agreements.
• Structure sets Hologen to own 70% of Hologen Neuro AI following completion, with MeiraGTx Neuro UK holding 30%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-048196), on April 24, 2026, and is solely responsible for the information contained therein.